Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Study backs heart failure drug Plavix

  • Comment

The drug Plavix improves the survival chances of people with heart failure, according to a study

Researchers say it improves the survival chances of people with heart failure, who had previously suffered a heart attack but had not had angioplasty treatment to clear their arteries.

The Danish study of Plavix, a Bristol-Myers Squibb drug also widely referred to as clopidogrel, is of “unquestionable practical importance”, according to Victor Serebruany at the HeartDrug Research Labs at John Hopkins University in the US.

The merit of using clopidogrel for heart failure has long been debated.

The results of the study are published in the Journal of the American College of Cardiology.

After 18 months, 32.2% of high-risk patients in the group not treated with Plavix died versus 28.1%in the group that did receive it.

The statistics could have “considerable clinical impact,” the researchers wrote, urging a better understanding of the benefits of using the drug.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs